98%
921
2 minutes
20
Objective: To assess the efficacy of low-dose aspirin in the prevention of adverse outcomes in low-risk, nulliparous singleton pregnancies.
Data Sources: PubMed, Ovid MEDLINE, Scopus, Cochrane Library, clinicaltrials.gov, and ScienceDirect were searched from their inception to August 5, 2023.
Eligibility Criteria For Selecting Studies: Randomized clinical trials comparing low-dose aspirin with placebo or with no treatment in low-risk nulliparous singleton pregnancies were included. High-risk pregnancies, including prior preterm birth, prior preeclampsia, and those affected by maternal diabetes or chronic hypertension were excluded.
Data Appraisal And Synthesis Methods: The primary outcome was the incidence of preterm delivery at less than 37 weeks. The summary measures were reported as relative risk (RR) or as mean difference (MD) with a 95% confidence interval (CI).
Results: Ten trials, including 27,075 nulliparous low-risk pregnancies, were included. Overall, low-dose aspirin was associated with no significant differences in preterm birth less than 37 weeks (RR 0.90, 95% CI 0.73-1.09) and less than 34 weeks (RR 0.62, 95% CI 0.37-1.05) compared to control. Patients who took 100 mg daily of aspirin prior to 16 weeks had a significantly lower risk of preterm birth at less than 37 weeks (RR: 0.45, 95% CI: 0.35-0.59), as did, to a lower magnitude, those who began aspirin 100 mg daily after 16 weeks (RR: 0.88, 95% CI: 0.80-0.97). Those who took 100 mg daily of aspirin were at a lower risk of preterm birth at less than 37 weeks than those who took between 60 and 81 mg of daily aspirin (RR: 0.39, 95% CI: 0.31-0.48). No statistically significant differences were found in the incidence of hypertensive disorders of pregnancy, perinatal or neonatal death.
Conclusions: Low-dose aspirin at 100 mg daily reduces the incidence of preterm birth at less than 37 weeks in low-risk, nulliparous pregnancies and may be most helpful if initiated prior to 16 weeks. El resumen está disponible en Español al final del artículo.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajogmf.2024.101595 | DOI Listing |
Clin Neuroradiol
September 2025
Department of Neurology, Soroka Medical Center, Beer Sheva, Israel.
Purpose: Emergent intracranial stenting (EICS) has demonstrated efficacy in managing intracranial stenosis in patients undergoing mechanical thrombectomy (MT) for acute ischemic stroke. However, an optimal pharmacological regimen balancing thrombosis prevention and hemorrhagic risk following stent deployment remains undefined. This study aimed to assess the safety and efficacy of prophylactic low-dose intra-arterial Eptifibatide following EICS.
View Article and Find Full Text PDFInt J Pharm
September 2025
Department of Veterinary Medicine, Central Animal Facility, Amrita Institute of Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa Vidyapeetham, Kochi, Kerala 682041, India.
The clinical use of gemcitabine (GEM), a frontline chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC), is limited by its short half-life, rapid systemic clearance, associated dose-limiting toxicities and a faster development of resistance in pancreatic cancer. Aspirin (ASP), a repurposed NSAID, has been shown to sensitize PDAC cells to GEM through modulation of multiple oncogenic and inflammatory pathways. However, its clinical use is restricted by dose-dependent gastrointestinal toxicity.
View Article and Find Full Text PDFBackground: In the presence of a potent P2Yinhibitor such as prasugrel, the additional clinical antithrombotic benefit of aspirin is unclear. The feasibility of prasugrel monotherapy without aspirin after percutaneous coronary intervention (PCI) has been demonstrated in chronic coronary syndrome, but is yet to be assessed in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) and low anatomical complexity.
Methods And Results: ASET-Japan is a single-arm study investigating the safety of prasugrel 12-month monotherapy with a locally approved dose (loading 20 mg; maintenance 3.
Ann Med Surg (Lond)
September 2025
Department of Pediatrics, Faculty of Medicine, University of Aleppo, Aleppo University Hospital (AUH), Aleppo, Syria.
Introduction And Importance: To document a rare case of Sturge-Weber syndrome (SWS) Type I with acute neurological symptoms.
Case Presentation: An 11-year-old boy, previously diagnosed with Sturge-Weber syndrome (SWS) Type I, presented to the emergency department with acute neurological symptoms that included vomiting, headaches, left-sided hemiparesis, and right-sided deviation of the labial commissure.
Clinical Discussion: Sturge-Weber syndrome (SWS) is a rare neurocutaneous disorder characterized by facial port-wine stains, leptomeningeal angiomas, and ocular involvement.
PLoS One
August 2025
Department of Microbiology and Immunology, School of Diagnostic Medicine, Campus College of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Background: Despite virologic suppression with antiretroviral therapy (ART), immune activation (IA) in people living with HIV (PLHIV) remains high and is linked to non-AIDS complications. Alongside its other virologic and immunologic benefits, aspirin promisingly appears to lower the residual IA in PLHIV in small studies.
Methods: We conducted a double-blind, parallel-group randomised trial involving ART-naïve PLHIV initiating ART at recruitment.